Mainstreaming Cell & Gene Therapies
Development, manufacturing, regulation and market access
The cell and gene therapy (CGT) market is rapidly transitioning from ultra-niche cutting-edge science to approved and available therapies that can address previously intractable and often devastating diseases. A rich pipeline of CGTs at various stages of development looks set to maintain that momentum for some time yet.
Whitepaper
Considerations for DTx clinical trials in CNS indications. Please login or register to access all premium content and additional website features.